Evidence map›Paper›PMID 41860372›Full record

ArticleJournal of Alzheimer's disease : JAD2026

Lecanemab alters basement membrane collagen IV in viable microvessels isolated from brains with high Alzheimer's disease neuropathology.

Mamatha Damodarasamy, Gustavo J Hernandez, Richard S Johnson, C Dirk Keene, Caitlin S Latimer, Michael J MacCoss, William A Banks, Michelle A Erickson, May J Reed

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mamatha DamodarasamyDepartment of Medicine, Division of Gerontology and Geriatric Medicine, University of Washington, Seattle, WA, USA.
Gustavo J HernandezDepartment of Medicine, Division of Gerontology and Geriatric Medicine, University of Washington, Seattle, WA, USA.
Richard S JohnsonDepartment of Genome Sciences, University of Washington, Seattle, WA, USA.
C Dirk KeeneDepartment of Laboratory Medicine and Pathology, Division of Neuropathology, University of Washington, Seattle, WA, USA.
Caitlin S LatimerDepartment of Laboratory Medicine and Pathology, Division of Neuropathology, University of Washington, Seattle, WA, USA.
Michael J MacCossDepartment of Genome Sciences, University of Washington, Seattle, WA, USA.
William A BanksDepartment of Medicine, Division of Gerontology and Geriatric Medicine, University of Washington, Seattle, WA, USA.
Michelle A EricksonDepartment of Medicine, Division of Gerontology and Geriatric Medicine, University of Washington, Seattle, WA, USA.
May J ReedDepartment of Medicine, Division of Gerontology and Geriatric Medicine, University of Washington, Seattle, WA, USA.ORCID 0000-0002-6917-9286

Funding

Translational pharmacoepidemiology: neuroprotection and neurotoxicity of antihypertensives and strong anticholinergicsU19AG066567 · NIA · KAISER FOUNDATION RESEARCH INSTITUTE · PI Christine L MacDonald · 2021 to 2026
$80.4M
University of Washington Alzheimer's Disease Research CenterP30AG066509 · NIA · UNIVERSITY OF WASHINGTON · PI Amanda D. Boyd · 2020 to 2026
$29.0M
Amyloid Beta and Collagen IV Interactions in the Brain Microvasculature in Alzheimers DiseaseR01AG087226 · NIA · UNIVERSITY OF WASHINGTON · PI MAY J REED · 2024 to 2026
$1.9M
Viable Microvessels for the Study of the Microvasculature in Alzheimer's DiseaseR21AG073676 · NIA · UNIVERSITY OF WASHINGTON · PI REED, MAY J · 2021 to 2022
$428k
The Microvasculature in Alzheimer’s Disease: Viable Microvessels for Studies of Brain Endothelial and Glycocalyx HealthR03AG075397 · NIA · UNIVERSITY OF WASHINGTON · PI REED, MAY J · 2022 to 2022
$156k
The Brain Microvasculature, Hyaluronan, and AgingR03AG051071 · NIA · UNIVERSITY OF WASHINGTON · PI REED, MAY J · 2015 to 2016
$155k
NIA NIH HHS P30 AG066509NIA NIH HHS R01 AG087226NIA NIH HHS R03 AG051071NIA NIH HHS R03 AG075397NIA NIH HHS R21 AG073676NIA NIH HHS U19 AG066567
6 · The paper itself

Abstract

Amyloid-β (Aβ) can deposit in or near the microvascular basement membrane (BM) in Alzheimer's disease (AD). We examined the effect of the Aβ binding antibody, lecanemab, on BM collagen IV (Col-IV) using viable brain microvessels (MV) isolated from human postmortem brain tissue with high AD neuropathologic change (ADNC=3, 16 females (mean 86 years), 11 males (mean 81 years)). MVs were exposed to lecanemab or isotype for 4 days and examined for Col-IV related outcomes: western blotting, capillary electrophoresis, RT-PCR, and degraded Col-IV. We find a subset of MV from some donors demonstrate Col-IV changes that could cause microvascular injury when exposed to lecanemab.

Indexed as

Alzheimer DiseaseBasement MembraneBrainCollagen Type IVMicrovesselsAgedAged, 80 and overFemaleHumansMaleCollagen Type IVAlzheimer's diseaseamyloid-betabasement membranecollagen IVextracellular matrixlecanemabmicrovasculature

Identifiers

PMID41860372
PMCPMC13007713

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.